Literature DB >> 23708712

Chylothorax after esophagectomy for cancer: impact of the surgical approach and neoadjuvant treatment: systematic review and institutional analysis.

Michael Kranzfelder1, Ralf Gertler, Alexander Hapfelmeier, Helmut Friess, Marcus Feith.   

Abstract

BACKGROUND: Esophagectomy is a challenging operation with considerable potential for postoperative complications, including chylothorax.
METHODS: Because no randomized controlled trial or metaanalysis is available to clarify the incidence of chylothorax in esophageal cancer surgery, the authors analyzed their own institutional data for 1,856 patients and performed a systematic review using the MEDLINE database (9,794 patients) to identify risk factors, compare success rates of therapeutic approaches, and investigate long-term outcomes.
RESULTS: The overall institutional chylothorax rate was 2 % (n = 39). Reoperation was performed for 69 % of the patients. No significant difference was noted between the transthoracic and transhiatal approaches. Regression analysis showed neoadjuvant treatment (odds ratio [OR], 0.302; p = 0.001) and tumor type (OR, 0.304; p = 0.002) to be independent risk factors. The systematic review included 12 studies. Chylothorax occurred for 2.6 % of the patients. Treatment favored reoperation in five studies (70-100 %) and a conservative approach in four studies (58-72 %), with equal mortality rates. No significant difference was found between the transthoracic and transhiatal approaches.
CONCLUSION: Chylothorax rates are low in high-volume centers (2-3 %). No significant difference was noted between the transthoracic and transhiatal approaches. Neoadjuvant treatment and tumor type were shown to be independent risk factors. Treatment concept (reoperation vs conservative treatment) did not affect long-term survival.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23708712     DOI: 10.1007/s00464-013-2991-7

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  39 in total

1.  Chylothorax complicating esophagectomy for cancer: a plea for early thoracic duct ligation.

Authors:  S Merigliano; D Molena; A Ruol; G Zaninotto; M Cagol; S Scappin; E Ancona
Journal:  J Thorac Cardiovasc Surg       Date:  2000-03       Impact factor: 5.209

2.  The nonoperative treatment of traumatic chylothorax.

Authors:  J V MALONEY; F C SPENCER
Journal:  Surgery       Date:  1956-07       Impact factor: 3.982

3.  Thoracoscopic management of chylothorax complicating esophagectomy.

Authors:  L Bonavina; G Saino; D Bona; M Abraham; A Peracchia
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2001-12       Impact factor: 1.878

4.  Postesophagectomy chylothorax: incidence, risk factors, and outcomes.

Authors:  Rachit D Shah; James D Luketich; Matthew J Schuchert; Neil A Christie; Arjun Pennathur; Rodney J Landreneau; Katie S Nason
Journal:  Ann Thorac Surg       Date:  2012-01-15       Impact factor: 4.330

5.  Transhiatal esophagectomy: clinical experience and refinements.

Authors:  M B Orringer; B Marshall; M D Iannettoni
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

6.  Management of chylothorax by percutaneous catheterization and embolization of the thoracic duct: prospective trial.

Authors:  C Cope; R Salem; L R Kaiser
Journal:  J Vasc Interv Radiol       Date:  1999-10       Impact factor: 3.464

Review 7.  Transhiatal versus Ivor-Lewis oesophagectomy: is there a difference?

Authors:  R Rindani; C J Martin; M R Cox
Journal:  Aust N Z J Surg       Date:  1999-03

8.  Postoperative chylothorax.

Authors:  R J Cerfolio; M S Allen; C Deschamps; V F Trastek; P C Pairolero
Journal:  J Thorac Cardiovasc Surg       Date:  1996-11       Impact factor: 5.209

9.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.

Authors:  Jan B F Hulscher; Johanna W van Sandick; Angela G E M de Boer; Bas P L Wijnhoven; Jan G P Tijssen; Paul Fockens; Peep F M Stalmeier; Fiebo J W ten Kate; Herman van Dekken; Huug Obertop; Hugo W Tilanus; J Jan B van Lanschot
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

10.  Treatment of postsurgical chylothorax with fibrin glue.

Authors:  W Stenzl; B Rigler; K H Tscheliessnigg; A Beitzke; H Metzler
Journal:  Thorac Cardiovasc Surg       Date:  1983-02       Impact factor: 1.827

View more
  19 in total

1.  Localization of thoracic duct using heavily T2W MRI for intractable post-esophagectomy chylothorax-a case report.

Authors:  Yi-Chien Chang; Yi-Ting Yen; Ming-Chung Chang; Yau-Lin Tseng
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

2.  Posterior retroperitoneoscopic thoracic duct ligation: a novel surgical approach.

Authors:  B Seeliger; P F Alesina; M K Walz
Journal:  Surg Endosc       Date:  2018-05-31       Impact factor: 4.584

3.  Clinical usefulness of the surgical Apgar score for estimating short-term and prognostic outcomes after esophagectomy.

Authors:  Naoya Yoshida; Hideo Baba
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

4.  Etiological approach of chylothorax in Babol, northern Iran.

Authors:  Novin Nikbakhsh; Mohammad Zamani; Askari Noorbaran; Ali Naghshineh; Danial Rastergar-Nejad
Journal:  Caspian J Intern Med       Date:  2017

Review 5.  Management options for post-esophagectomy chylothorax.

Authors:  Vaibhav Kumar Varshney; Sunita Suman; Pawan Kumar Garg; Subhash Chandra Soni; Pushpinder Singh Khera
Journal:  Surg Today       Date:  2020-09-17       Impact factor: 2.549

6.  [Treatment of chylothorax].

Authors:  M Schirren; S Sponholz; J Schirren
Journal:  Chirurg       Date:  2018-07       Impact factor: 0.955

7.  Surgical treatments for esophageal cancers.

Authors:  William H Allum; Luigi Bonavina; Stephen D Cassivi; Miguel A Cuesta; Zhao Ming Dong; Valter Nilton Felix; Edgar Figueredo; Piers A C Gatenby; Leonie Haverkamp; Maksat A Ibraev; Mark J Krasna; René Lambert; Rupert Langer; Michael P N Lewis; Katie S Nason; Kevin Parry; Shaun R Preston; Jelle P Ruurda; Lara W Schaheen; Roger P Tatum; Igor N Turkin; Sylvia van der Horst; Donald L van der Peet; Peter C van der Sluis; Richard van Hillegersberg; Justin C R Wormald; Peter C Wu; Barbara M Zonderhuis
Journal:  Ann N Y Acad Sci       Date:  2014-09       Impact factor: 5.691

8.  Incidence and management of chylothorax after esophagectomy.

Authors:  Longsheng Miao; Yawei Zhang; Hong Hu; Longfei Ma; Yihua Shun; Jiaqing Xiang; Haiquan Chen
Journal:  Thorac Cancer       Date:  2015-02-26       Impact factor: 3.500

Review 9.  Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.

Authors:  Panagiota Papanagnou; Panagiotis Baltopoulos; Maria Tsironi
Journal:  Ther Clin Risk Manag       Date:  2015-05-18       Impact factor: 2.423

10.  Transabdominal approach for chylorrhea after esophagectomy by using fluorescence navigation with indocyanine green.

Authors:  Takeshi Matsutani; Atsushi Hirakata; Tsutomu Nomura; Nobutoshi Hagiwara; Akihisa Matsuda; Hiroshi Yoshida; Eiji Uchida
Journal:  Case Rep Surg       Date:  2014-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.